Noort W A, Wilpshaar J, Hertogh C D, Rad M, Lurvink E G, van Luxemburg-Heijs S A, Zwinderman K, Verwey R A, Willemze R, Falkenburg J H
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Bone Marrow Transplant. 2001 Jul;28(2):163-71. doi: 10.1038/sj.bmt.1703120.
Umbilical cord blood (UCB), bone marrow (BM) and mobilized peripheral blood (mPB) are used as sources of hematopoietic stem cells for transplantation. The NOD/SCID mouse model was used to compare the lineage-specific repopulating potential of CD34(+) cells derived from these sources. Six to 8 weeks after transplantation, blood, BM, spleen, liver and thymus, were harvested, and analyzed by flow cytometry using CD34, CD45, myeloid, and lymphoid lineage-specific antibodies. Fifty percent engraftment of human cells in bone marrow of mice was estimated to be reached with 0.55 x 10(6) CD34(+) UCB cells or with 7.9 x 10(6) CD34(+) cells from adult sources, illustrating a 10-fold superiority of UCB CD34(+) cells to engraft NOD/SCID mice. Lineage-specific characterization of engrafted human cells showed that the high engraftment potential of CD34(+) cells from UCB was due to a preferential B cell development (2-81%). In contrast, comparable percentages of myeloid cells were found following transplantation of CD34(+) cells from UCB, BM and mPB (1-38%), and occurred at significant levels only at relatively high doses. Since the CD34 content of UCB transplants is usually at least one log lower than of transplant from adult sources, these results correspond to the clinical findings with UCB transplantation showing a relatively high overall engraftment, but delayed myeloid recovery.
脐带血（UCB）、骨髓（BM）和动员外周血（mPB）被用作造血干细胞移植的来源。使用NOD/SCID小鼠模型比较源自这些来源的CD34(+)细胞的谱系特异性再增殖潜力。移植后6至8周，采集血液、骨髓、脾脏、肝脏和胸腺，并使用CD34、CD45、髓系和淋巴系特异性抗体通过流式细胞术进行分析。估计用0.55×10(6)个CD34(+) UCB细胞或7.9×10(6)个来自成人来源的CD34(+)细胞可使小鼠骨髓中人类细胞的植入率达到50%，这表明UCB CD34(+)细胞植入NOD/SCID小鼠的能力比成人来源的细胞高10倍。对植入的人类细胞进行谱系特异性表征表明，UCB中CD34(+)细胞的高植入潜力归因于优先的B细胞发育（2 - 81%）。相比之下，在移植来自UCB、BM和mPB的CD34(+)细胞后，发现髓系细胞的百分比相当（1 - 38%），并且仅在相对高剂量时才达到显著水平。由于UCB移植中CD34的含量通常比成人来源的移植至少低一个对数，这些结果与UCB移植的临床发现一致，即总体植入率相对较高，但髓系恢复延迟。
